Medicine
Cometriq 20 mg capsule
Cometriq 20 mg capsule is a prescription medicine containing Cabozantinib s-malate for oral use, marketed by Exelixis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store COMETRIQ at 20°C to 25°C (68°F to 77°F), excursions are permitted from…
Key facts
- Active ingredient (INN)
- Cabozantinib s-malate
- Brand
- Cometriq
- Strength
- 20 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 4 blister pack
- Marketing authorisation holder
- Exelixis
- Manufacturer
- Exelixis
- Origin register
- US FDA, United States
- Storage
- Store COMETRIQ at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 November 2012
- Identifiers
- RxCUI 1363273, 1363279, 1363281 +7DailyMed set ID 1a0c3bea-c87b-4d25-bb44-5f0174da6b34NDC 42388-013Application NDA203756
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 carton / 21 capsule in 1 blister pack | 42388-013-14 | Exelixis | 29 November 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 November 2012 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cabozantinib s-malate
Clinical summary
Cabozantinib s-malate is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). It is available as tablets and capsules for oral use. MedsAcross supplies Cabozantinib s-malate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cabozantinib s-malateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- COMETRIQ prescribing information (Exelixis) · U.S. National Library of Medicine, DailyMed
Need Cometriq 20 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.